Canakinumab
Canakinumab (pronunciation: /ˌkænəˈkɪnjuːmæb/) is a monoclonal antibody designed for the treatment of various autoinflammatory syndromes. It is a human monoclonal antibody targeted at interleukin-1 beta.
Etymology
The name "Canakinumab" comes from the words "canakin", an old term for a small can or drinking vessel, and "mab", an abbreviation for monoclonal antibody. The "canakin" part of the name is a reference to the drug's ability to "hold" or "contain" the inflammatory response, much like a vessel holds liquid.
Usage
Canakinumab is used for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including familial cold autoinflammatory syndrome and Muckle-Wells syndrome. It is also used in the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA), Adult-Onset Still's Disease (AOSD), and Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS).
Mechanism of Action
Canakinumab works by blocking the action of interleukin-1 beta. This protein is part of the body's immune response and is produced in excess in people with autoinflammatory syndromes. By blocking the action of interleukin-1 beta, canakinumab helps to reduce the symptoms of these conditions.
Related Terms
- Monoclonal Antibody
- Interleukin-1 Beta
- Cryopyrin-Associated Periodic Syndromes
- Systemic Juvenile Idiopathic Arthritis
- Adult-Onset Still's Disease
- Tumor Necrosis Factor Receptor Associated Periodic Syndrome
External links
- Medical encyclopedia article on Canakinumab
- Wikipedia's article - Canakinumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski